Estradiol Levels & Breast Cancer Risk and Your Genetics
What Is Plasma Estradiol and Why Does It Matter for Breast Cancer?
Estradiol (E2) is the most biologically potent of the three major endogenous estrogens and the primary driver of estrogen receptor (ER) signaling in breast tissue. In postmenopausal women, circulating estradiol is produced primarily through peripheral aromatization of androgen precursors — a process occurring in adipose tissue, skin, and muscle — rather than from ovarian secretion. Because ER-positive breast cancers are fueled by estrogen signaling, postmenopausal estradiol levels are clinically relevant both as a breast cancer risk factor and as a target for adjuvant hormone suppression therapy.
Aromatase inhibitors (AIs) are standard adjuvant therapy for postmenopausal women with ER-positive breast cancer. They suppress residual estradiol production to near-undetectable levels. However, plasma estradiol varies between patients even on AI therapy, partly reflecting genetic differences in aromatase expression and estrogen metabolism. Identifying the genetic determinants of plasma estradiol in this clinical context illuminates mechanisms underlying residual estrogen exposure and inter-individual variation in estrogen levels.
How Genetics Influence Estradiol Levels
Genome-wide association studies in postmenopausal women have identified genomic loci influencing plasma estradiol concentrations. These loci implicate pathways involved in aromatase (CYP19A1) transcriptional regulation, steroidogenesis, and estrogen receptor biology. Genetic variation in these pathways may influence how much estradiol is produced in peripheral tissues — contributing to inter-individual differences in circulating estradiol levels independently of age, body weight, and hormonal treatment status.
Key Genes and Variants
Variants near TSPYL5 (testis-specific Y-like protein 5) showed the strongest genome-wide association with plasma estradiol in a discovery GWAS of postmenopausal breast cancer patients. Functional studies from the same research established that TSPYL5 acts as a transcription factor for CYP19A1 (aromatase), the enzyme responsible for converting androgens to estrogens in peripheral tissues. TSPYL5 knockdown reduced aromatase expression, while TSPYL5 overexpression increased it — establishing a plausible causal pathway from the chromosome 8 GWAS signal to circulating estradiol concentration. One variant (rs2583506) in the TSPYL5 region creates a functional estrogen response element, forming an E2-responsive autoregulatory loop in which estradiol induces further TSPYL5 expression in cells carrying variant alleles.
Variants near JAK1 (Janus kinase 1) have been identified among associated loci in estradiol plasma level analyses. JAK1 encodes a non-receptor tyrosine kinase central to cytokine and growth factor signaling, with known interactions with estrogen receptor signaling pathways. Variants near CPQ (carboxypeptidase Q), DSCAM (Down syndrome cell adhesion molecule), PLCB1 (phospholipase C beta 1), and PDLIM5 (PDZ and LIM domain protein 5) have also been identified within the associated gene set, though the mechanisms connecting these loci to estradiol regulation require further investigation.
What the Research Shows
Liu et al. (2013) conducted a discovery GWAS to identify genetic factors associated with variation in plasma estradiol, using DNA from 772 postmenopausal women with ER-positive breast cancer collected prior to aromatase inhibitor therapy initiation (Mol Endocrinol, 2013).1
Variants near TSPYL5 at chromosome 8 reached genome-wide significance for association with plasma estradiol levels (lead SNP rs1864729, P=3.49×10⁻⁸; 17 additional TSPYL5-region variants P<5×10⁻⁸). Functional experiments established that TSPYL5 regulates aromatase (CYP19A1) expression via the skin/adipose I.4 promoter, with variant TSPYL5 genotypes showing higher E2-dependent TSPYL5 expression — revealing a novel mechanism for genetic control of peripheral estrogen synthesis (Liu et al., 2013).1
Understanding Your Result
A higher genetic score for this trait reflects greater inherited tendency toward elevated plasma estradiol levels, as characterized in postmenopausal women with ER-positive breast cancer. Higher postmenopausal estradiol is associated with increased breast cancer risk and may influence the degree of estrogen suppression achievable on aromatase inhibitor therapy. This represents a population-level statistical association — it reflects relative tendency compared to others in the reference population, not a certain clinical outcome for any individual.
Plasma estradiol levels are also substantially influenced by body composition (especially adipose tissue mass, the primary site of postmenopausal aromatization), alcohol intake, physical activity, and medications. Genetic susceptibility to higher estradiol is one contributor to a complex multifactorial picture that also depends heavily on these modifiable factors.
This genetic information is for educational and informational purposes only. Results do not constitute a clinical evaluation.
Lifestyle and Considerations
Maintaining a healthy body weight is the most impactful modifiable factor for postmenopausal estradiol levels, as adipose tissue is the major site of peripheral aromatase activity and estrogen synthesis after menopause. Prospective cohort studies consistently show that higher adiposity correlates with higher postmenopausal circulating estrogens. Regular aerobic exercise is associated with lower circulating estradiol in postmenopausal women in observational and intervention studies. Limiting alcohol consumption is associated with lower estrogen levels, as alcohol promotes estrogen synthesis and reduces hepatic estrogen clearance.
Dietary patterns high in fiber and plant-based foods may modestly support estrogen metabolism and clearance. For women with ER-positive breast cancer or at elevated breast cancer risk, questions about estradiol monitoring and hormone-related risk should be discussed with an oncologist or relevant specialist who can evaluate the full clinical context.
Frequently Asked Questions
Why is higher plasma estradiol considered detrimental in this trait?
This GWAS was conducted specifically in postmenopausal women with ER-positive breast cancer — a tumor type where estrogen receptor signaling directly drives tumor cell proliferation and survival. Higher circulating estradiol provides more ligand to activate ER signaling in tumor cells, and elevated postmenopausal estradiol is associated with increased breast cancer incidence and recurrence risk in epidemiological studies. Additionally, higher estradiol may limit the efficacy of aromatase inhibitor therapy, which aims to suppress peripheral estrogen production to near-undetectable levels as adjuvant breast cancer treatment.
What is aromatase and why does TSPYL5 matter?
Aromatase (encoded by CYP19A1) is the rate-limiting enzyme for estrogen biosynthesis — it converts androstenedione and testosterone into estrone and estradiol. In postmenopausal women, aromatase expressed in adipose and skin tissue is the primary source of circulating estrogens. TSPYL5 acts as a transcriptional regulator of CYP19A1 through the skin/adipose-specific I.4 promoter, meaning genetic variation at the TSPYL5 locus can alter how much aromatase is produced in peripheral tissues. Higher TSPYL5 activity drives higher aromatase expression and consequently higher plasma estradiol.
Does this genetic score apply to premenopausal women?
This GWAS was conducted exclusively in postmenopausal women with ER-positive breast cancer. In premenopausal women, circulating estradiol is produced primarily by the ovaries through a fundamentally different hormonal regulatory mechanism. The TSPYL5 and peripheral aromatization loci identified in this GWAS reflect biology specifically relevant to the postmenopausal context. Whether these variants influence estradiol in premenopausal women through the same mechanisms is not established by this research, and the clinical interpretation would differ substantially.
What lifestyle factors can help lower postmenopausal estradiol levels?
Maintaining a healthy body weight is the most impactful modifiable factor, as adipose tissue is the major site of postmenopausal estrogen production. Higher body mass index consistently correlates with higher postmenopausal estradiol in epidemiological studies. Regular aerobic exercise, limiting alcohol intake, and high-fiber dietary patterns are each independently associated with lower circulating estrogens in postmenopausal women in observational research, though effect sizes vary across cohorts and study designs.
How does JAK1 relate to estrogen biology?
JAK1 (Janus kinase 1) mediates signaling downstream of multiple cytokine and growth factor receptors, including pathways that interact with estrogen receptor signaling cascades. Estrogen receptor activation can engage JAK-STAT signaling, and conversely, cytokine-JAK pathways can modulate ER activity and downstream gene expression. Variants near JAK1 in estradiol GWAS analyses may reflect regulatory cross-talk between JAK1-dependent signaling and aromatase expression or estrogen receptor pathway activity, though the specific mechanisms remain under investigation.
References
- Liu M, Goss PE, Ingle JN, et al. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol. 2013;27(4):657-670. (PMID 23518928)